Method of making dual chamber flexible container

Abstract

A multiple chamber container forming and filling method includes (i) forming at least one strong seal around a periphery of first and second sheets so as to leave an opening between the first and second sheets; (ii) forming a temporary peel seal across the opening; (iii) forming a mixing peel seal between the first and second sheets so as to separate a diluent chamber from a powdered drug chamber; (iv) adding diluent to the diluent chamber; (v) sterilizing the multiple chamber container including the diluent; (vi) opening the temporary peel seal in an aseptic environment; (vii) adding powdered drug to the powdered drug chamber through the opening; and (viii) strong sealing the opening so as to be closed.

Claims

1. A multiple chamber container forming and filling method comprising: forming at least one strong seal around a periphery of first and second sheets so as to leave an opening between the first and second sheets; forming a temporary peel seal across the opening, wherein forming the temporary peel seal across the opening includes leaving a smaller opening than the opening between the first and second sheets in the temporary peel seal to accept a gas injecting structure; forming a mixing peel seal between the first and second sheets so as to separate a diluent chamber from a powdered drug chamber; adding diluent to the diluent chamber; sterilizing the multiple chamber container including the diluent; opening the temporary peel seal in an aseptic environment; adding powdered drug to the powdered drug chamber through the opening; strong sealing the opening so as to be closed; and forming a delivery peel seal between the powdered drug chamber and an outlet of the multiple chamber container.

2. The multiple chamber container forming and filling method of claim 1, wherein the opening is a first opening, and wherein forming the at least one strong seal around the periphery of the first and second sheets includes leaving a second opening between the first and second sheets for adding the diluent.

3. The multiple chamber container forming and filling method of claim 2, which includes strong sealing the second opening so as to be closed prior to sterilizing the multiple chamber container.

4. The multiple chamber container forming and filling method of claim 1, wherein the delivery peel seal between the powdered drug chamber and the outlet of the multiple chamber container has a seal strength the same or lower than that of the mixing peel seal.

5. The multiple chamber container forming and filling method of claim 1, which includes inserting a gas into the powdered drug chamber through the smaller opening and closing the smaller opening after inserting the gas through the smaller opening.

6. The multiple chamber container forming and filling method of claim 1, which includes inserting gas into the powdered drug chamber prior to opening the temporary peel seal.

7. The multiple chamber container forming and filling method of claim 6, wherein the gas is at least one of an inerting gas or an oxygen getting gas.

8. The multiple chamber container forming and filling method of claim 6, wherein the gas separates the first and second sheets, and wherein opening the temporary peel seal includes suctioning the separated first and second sheets and pulling on the temporary peel seal.

9. The multiple chamber container forming and filling method of claim 1, wherein the opening and the temporary peel seal border the powdered drug chamber.

10. The multiple chamber container forming and filling method of claim 1, which includes sterilizing the powdered drug prior to adding the powdered drug to the powdered drug chamber through the opening.

11. A multiple chamber container forming and filling method comprising: forming at least one strong seal around a periphery of first and second sheets so as to leave an opening between the first and second sheets; forming a temporary peel seal across the opening, wherein forming the temporary peel seal across the opening includes leaving a smaller opening than the opening between the first and second sheets in the temporary peel seal to accept a gas injecting structure; forming a mixing peel seal between the first and second sheets so as to separate a diluent chamber from a powdered drug chamber; adding diluent to the diluent chamber; sterilizing the multiple chamber container including the diluent; drying the multiple chamber container and moving the multiple chamber container into a clean room forming an aseptic environment; opening the temporary peel seal in the clean room; adding powdered drug to the powdered drug chamber through the opening in the clean room; strong sealing the opening in the clean room so as to be closed; and forming a delivery peel seal in the clean room between the powdered drug chamber and an outlet of the multiple chamber container.

Description

BRIEF DESCRIPTION OF THE FIGURES

(1) FIG. 1A is a top-front perspective view of one embodiment of a dual chamber container or bag of the present disclosure.

(2) FIG. 1B is a top-front perspective view of the dual chamber bag of FIG. 1A showing opaque cover layers exploded or removed from the sheets of the container or bag.

(3) FIG. 2 is a front view of the dual chamber container or bag of FIGS. 1A and 1B.

(4) FIG. 3 is a rear view of the dual chamber container or bag of FIGS. 1A and 1B.

(5) FIG. 4 is a side view of the dual chamber container or bag of FIGS. 1A and 1B.

(6) FIG. 5 is a top plan view of the dual chamber container or bag of FIGS. 1A and 1B.

(7) FIG. 6 is a bottom plan view of the dual chamber container or bag of FIGS. 1A and 1B.

(8) FIGS. 7A to 7C are partially sectioned side views of the dual chamber container or bag illustrating one embodiment for a relative location between a delivery peel seal and opaque cover peel seals.

(9) FIGS. 8A to 8C are partially sectioned side views of the dual chamber container or bag illustrating another embodiment for a relative location between multiple delivery peel seals and opaque cover peel seals.

(10) FIG. 9 is an elevation partial sectioned view of one embodiment of the administration port of the dual chamber container or bag of the present disclosure.

(11) FIGS. 10A to 10D are front views illustrating different manufacturing stages of one embodiment for making a dual chamber container or bag of the present disclosure.

(12) FIG. 11 is a schematic diagram further illustrating the method of FIGS. 10A to 10D for making the dual chamber container or bag of the present disclosure.

(13) FIGS. 12A to 12E are front views illustrating different manufacturing stages of an alternative embodiment for making a dual chamber container or bag of the present disclosure.

(14) FIG. 13 is a schematic diagram illustrating in cooperation with FIGS. 12A to 12E an alternative embodiment for making the dual chamber container or bag of the present disclosure.

DETAILED DESCRIPTION

Dual Chamber Container or Bag

(15) Referring now to the drawings, FIGS. 1A to 9 illustrate various embodiments of a dual chamber container or bag 10. Dual chamber bag 10 includes a first sheet 12 sealed to a second sheet 14. Sheets 12 and 14 may each be made of a single layer or may instead include two or more layers laminated together or coextruded. For example, sheets 12 and 14 may each have three layers including a seal layer (closest to diluent and drug), a middle layer, and a skin layer (outer layer). The seal layer may include a compound of homo polypropylene (“homo PP”) and a propylene-ethylene copolymer (“EPR”), wherein amorphous domain EPR is finely dispersed in a homo PP matrix. The middle layer may include a compound of homo PP with a styrene elastomer (e.g., styrene ethylene butylene styrene (“SEBS”) or styrene ethylene propylene styrene (“SEPS”)). The skin layer may include a compound of homo PP and EPR, wherein the EPR is finely dispersed in a homo PP matrix, and wherein the content of EPR may be less than that of the seal layer.

(16) For purposes of illustration only, dual chamber bag 10 will be described in terms of how it is to be arranged for use with its administration port 16 located at the bottom of the bag and extending downwardly to aid gravity flow. Upper seam 30 is formed having a strong seal. A strong seal as used herein is a seal that will not rupture under the force applied by a user to open any of the peel seals discussed herein. In an embodiment, any strong seal discussed herein may have a seal strength of at least about 30 N/15 mm. A user will be instructed to press or roll bag 10 at a location containing the diluent to build fluid pressure to rupture the peel seals. A strong seal as used herein will not rupture under such fluid pressure. The seals of any of the seams discussed herein are typically sealed via heat sealing. Seal strength may be varied by controlling the seal temperature, for example.

(17) In a non-limiting example, upper seam 30 is a relatively wide seam, which may have a widest width from about 12 millimeters (“mm”) to about 25 mm, and which in one example instance is 18 mm. The length of upper seam 30 may be from about 150 mm to about 180 mm, and in one embodiment is 165 mm (the width of seam 30 may therefore be 10% to 11% of the length of the seam in one embodiment). The width of upper seam 30 as illustrated provides room and strength against tearing for one or more aperture 32, 34 and 36 formed in upper seam 30, which may be circular or oblong as illustrated. Aperture 34 may be used to hang bag 10 from an intravenous (“IV”) stand or pole, while apertures 32 and 36 may be used to position bag 10 for either one or both of sterilization and/or filling. In the illustrated embodiment, seam 30 is narrowed and rounded at corners 38a and 38b of diluent chamber 70, to (i) increase the internal volume of and (ii) avoid sharp corners for chamber 70.

(18) In an embodiment, upper seam at area 34a around oval 34 is reinforced either with additional material and/or additional sealing energy and/or additional sealing time. Reinforced area 34a helps to hold the entire weight of completely full bag 10 without tearing. Area 34a around oval 34 may include an additional piece of polymer material, which is welded to the rest of upper seam 30 to seal an aperture that allows diluent chamber 70 to be filled with liquid diluent.

(19) Side seams 40a and 40b in an embodiment are generally mirror images of each other and are numbered the same accordingly. Side seams 40a and 40b extend from upper seam 30 and, like seam 30, are formed having strong seals. Side seams 40a and 40b each include a narrow portion 42, which extends along the majority of the corresponding side of diluent chamber 70. In a non-limiting example, narrow portion 42 may have a width of about 4 mm to about 10 mm, and in one example instance is 6 mm. The length of narrow portion 42 will vary depending upon the size of bag 10, which may in non-limiting examples be provided in three different sizes, such as, a 100 milliliter (“mL”) diluent bag 10, a 100 mL diluent bag, a 200 mL diluent bag, and a 400 mL diluent bag. Different or additional sizes may also be provided, e.g., less than 100 mL and/or greater than 400 mL.

(20) Narrow portions 42 of side seams 40a and 40b extend to curved or angled corners 44, which increase the strong sealed area in a rounded, elliptical, parabolic or triangular way. Curved or angled corners 44 provide room and strength for one or more aperture 46, e.g., circular aperture, if desired, which may also be used to position bag 10 for either one or both of sterilization and/or filling. Curved or angled corners 44 also funnel diluent within diluent chamber 70 towards a mixing peel seal 60 discussed in detail below. Funneling diluent towards mixing peel seal 60 helps to maximize the seal opening pressure per force applied by the user.

(21) Powdered drug portions 48a and 48b of side seams 40a and 40b, respectively, extend from curved or angled corners 44 of the side seams to a bottom seam 50. In a non-limiting example, powdered drug portions 48a and 48b of the side seams may be from about 5 mm to about 12 mm wide, and in one example instance may be 10 mm wide. In a non-limiting example, the lengths of powdered drug portions 48a and 48b of the side seams extending from curved or angled corners 44 to bottom seam 50 may each be about 100 mm to about 120 mm. As discussed, narrow portions 42, curved or angled corners 44, and powdered drug portions 48a and 48b of side seams 40a and 40b, respectively, are each formed having strong seals.

(22) Bottom seam 50 is likewise a strong seam and in a non-limiting example may be from about 145 mm long to about 170 mm long, and in one example instance may be 155 mm long. Bottom seam 50 may therefore be longer or shorter than upper seam 30. The width of bottom seam 50 varies due to the shape of powdered drug chamber 80 and the shape of an administration area 98 located between drug chamber 80 and administration port 16. In an embodiment, the width of bottom seam 50 is greatest at the corners of bottom seam 50, which may include or define apertures 52 that may be used to position bag 10 for sterilization and/or filling, while the width of bottom seam 50 is smallest at its center section 54, which is sealed to administration port 16.

(23) Administration port 16 in the illustrated embodiment includes a hollow port body 18, which may be a molded, e.g., injection molded, rigid PP structure. Administration port 16 includes a port body 18 having a tapered sealing portion 20 that extends to a cylindrical outlet portion 22, which resides outside of bag 10. Tapered sealing portion 20 is sealed between sheets 12 and 14 at center section 54 of seam 50, e.g., via ultrasonic welding, heat sealing, solvent bonding, and the like. The tapered shape of sealing portion 20 prevents sheets 12 and 14 at center section 54 from having to form a sharp radius to seal around a circular port section, which could lead to a faulty seal. Outlet portion 22 of port body 18 includes a flange 22a at its end for receiving a spike from a mating administration set and to provide an increased area for sealing to a tear strip 28.

(24) In the illustrated embodiment, a compliant or compressible insert or sleeve 24 is fitted sealingly inside outlet portion 22 and flange 22a of administration port 16, and may be formed within the port via successive molding steps. Insert or sleeve 24 may be formed from a medically safe rubber, e.g., a thermoplastic elastomer (“TPE”), which accommodates a broad range of spike head diameters provided with the administration sets. Rubber insert 24 provides flexibility, e.g., compressibility, to accept standard sized diameter spikes and non-standard or differently sized spikes. Outlet portion 22 of administration port 16 may be formed, e.g., injection molded, with a membrane 26, which is pierced by the spike of the administration set to enable the reconstituted drug within bag 10 to flow to the patient. In an alternative embodiment, membrane 26 may be formed instead with insert 24. A thin plastic tear strip 28 includes a middle section that is peel sealed to flange 22a of outlet portion 22, maintaining sterility and preventing contaminants from entering and contacting rubber insert 24, wherein such contaminants could be carried into the interior of bag 10 upon spiking. Either exposed end of tear strip 28 may be grasped by the user to tear strip 28 from flange 22a for spiking membrane 26 of administration port 16.

(25) FIG. 1B perhaps best illustrates that a mixing peel seal 60 is located between diluent chamber 70 and powdered drug chamber 80. In one embodiment, the width of mixing peel seal 60 is from about 10 mm to about 20 mm, and is in one embodiment 15 mm. The length of peel seal 60 may extend from (i) curved or angled corner 44 to curved or angled corner 44 of side seams 40a and 40b or (ii) powdered drug portion 48a to powdered drug portion 48b of side seams 40a and 40b, respectively. The force needed to open peel seal 60 in one embodiment is roughly one-quarter to one-third of the force needed to separate any of upper seam 30 or narrow portions 42 of side seams 40a and 40b, forming the remainder of diluent chamber 70. In an embodiment, the strength of mixing peel seal 60 may be about 2 to 12 N/15 mm. Mixing peel seal 60 is sufficiently strong and liquid-tight to prevent diluent in diluent chamber 70 from flowing into powdered drug chamber 80.

(26) Diluent chamber 70 as mentioned above may be sized differently in non-limiting examples to hold different maximum amounts of diluent, e.g., 100 mL, 200 mL or 400 mL. In a non-limiting example, diluent chamber 70 may have a side-to-side width from about 140 mm to about 160 mm, and in one example instance a width of 153 mm. In a non-limiting example, diluent chamber 70 may have a top (starting from area 34a around oval 34) to bottom height ranging from about 70 mm to about 170 mm. Diluent chamber 70 as illustrated in FIGS. 1A to 4 includes a pouch 72 formed from sheets 12 and 14, which may be preformed or which may be formed when diluent is added. In one embodiment, even when pouch 72 is filled with diluent, sheets 12 and 14 are at least substantially upstretched. In an embodiment, pouch 72 is not filled completely with diluent. Thus, a diluent chamber 70 capable of holding 100 mL, for example, may be filled with only 50 or 75 mL, and likewise for the 200 mL and 400 mL larger diluent chambers 70, to provide a desired amount of diluent for dissolving and delivering the drug in drug chamber 80.

(27) Powdered drug chamber 80 is located on the other side of mixing peel seal 60 from diluent chamber 70. Powdered drug chamber 80 is sized to hold enough powdered drug to provide any feasible drug dose to the patient based upon the volume of diluent provided in diluent chamber 70. In a non-limiting example, powdered drug chamber 80 may have a side to side (inner edges of side 84a to inner edge of side 84b) width from about 130 mm to about 150 mm, and in one example instance have a width of 140 mm. In one non-limiting example, powdered drug chamber 80 may have a top (at mixing peel seal 60) to bottom (at delivery peel seal 90) height ranging from about 70 mm to about 170 mm.

(28) In the illustrated embodiment, powdered drug chamber 80 includes an upper edge 82 formed by mixing peel seal 60, and two sides 84a and 84b formed by powdered drug portions 48a and 48b, respectively, of side seams 40a and 40b, which extend perpendicular to upper edge 82. Powdered drug chamber 80 in the illustrated embodiment also includes two angled sides 86a and 86b formed by bottom seam 50, which extend to center section 54 sealed to administration port 16 of bottom seam 50. The two angled sides 86a and 86b are interrupted by delivery peel seal 90 to form the lower edge of powdered drug chamber 80. Powdered chamber 80 may be evacuated or purged with inert gas before filling to prevent air from contacting the drug. In FIG. 1B, with dual chamber bag 10 hanging in the operable position such that administration port 16 points downwardly, a powdered drug 88 due to gravity falls due to gravity so as to rest on the top of delivery peel seal 90.

(29) Drug 88 may be any powdered drug capable of dissolving with a diluent, including but not limited to (i) powdered drug preparations for the prevention and treatment of viral diseases, auto-immune and inflammatory diseases, cardiovascular and pulmonary diseases, central nervous system diseases, peripheral neurological system diseases, pain, dermatologic diseases, gastro-intestinal diseases, infectious-related diseases, metabolic diseases, oncologic diseases, ophthalmic diseases, respiratory diseases, digital ulcers, and cerebrovascular diseases, (ii) vaccines, (iii) anxiolytics, (iv) anti-allergics, and (v) anti-infectives.

(30) In a non-limiting example, delivery peel seal 90 may be about 3 mm to about 10 mm wide and about 50 mm to about 90 mm long and have the same seal strength (force required to open), greater seal strength or a lower seal strength than mixing peel seal 60. In an embodiment, peel seal 90 may have a seal strength of approximately 2 to 10 N/15 mm, which is the same or lower than the seal strength of mixing peel seal 60. Delivery peel seal 90 in the illustrated embodiment has a non-linear shape, such as a trapezoidal shape. In any case, delivery peel seal 90 includes a central portion 92 that extends around an administration area 98 located between sheets 12 and 14 and directly adjacent to tapered sealing portion 20 of administration port 16, which is sealed to center section 54 of bottom seam 50. Placing central portion 92 instead closer to tapered sealing portion 20 runs the risk of inducing stress on peel seal 90 at portion 92 due to the sealing of sheets 12 and 14 to administration port 16, which may cause peel seal 90 to open inadvertently. Trapezoidally or otherwise extended central portion 92 of delivery peel seal 90 ensures that the peel seal 90 is not activated under stress until the user applies pressure via mixed drug and diluent.

(31) One aspect of the present disclosure is how chambers 70 and 80 interact during use via peel seals 60, 90/92 to help ensure that the opening mechanics of the dual chamber bag 10 are easy and fool proof. For example, (i) diluent and powdered drug 88 always mix before use, (ii) container 10 does not require a large manual effort to activate, and (iii) the sealing is nonetheless strong enough to withstand normal transportation and handling. Non-linear or trapezoidal portion 92, in addition to avoiding administration port 16, creates a stress concentration which in combination with the relative seal strengths of peel seals 60 and 90 help to meet the above-listed operational goals. Again, portion 92 may have any desired non-lineal shape.

(32) As discussed, one primary purpose for the shape of non-linear portion 92 of peel seal 90 is to space peel seal 90 at portion 92 away from tapered sealing portion 20, so that the tapered extended portion 92 is not placed under undue stress, which might cause the seal to begin to open. In the illustrated embodiment, an opaque removable cover layer 100 may be applied to one or both of sheets 12 and 14 to cover powdered drug chamber 80 and administration area 98 beneath central portion 92 of delivery peel seal 90. Opaque layers 100 may have the same side-to-side length as the length of bottom seam 50 and extend in height from a top (or above) mixing peel seal 60 downwardly past delivery peel seal 90. A bottom seal 102 of opaque layer 100, in the illustrated embodiment, has the same non-linear or trapezoidal shape as peel seal 90, including a jutting or trapezoidal portion 104 that matches portion 92 of peel seal 90. In this manner, the existence of tapered sealing portion 20 of administration port 16 does not adversely affect bottom seal 102 of opaque layer 100, e.g., by placing stress on the seal.

(33) In one embodiment illustrated in FIGS. 1A, 2 and 3, bottom seal 102 is located between delivery peel seal 90 and tapered sealing portion 20 of administration port 16. Trapezoidal portion 104 of bottom seal 102 may overlay a portion of administration area 98. Placing trapezoidal portion 104 of bottom seal 102 in such a location prevents bottom seal 102 from interfering (e.g., due to the formation of seal 102) with delivery peel seal 90 or powdered drug chamber 80. It should be appreciated that the location of trapezoidal portion 104 may cause peel seal 90 at portion 92 to be spaced further way from tapered sealing portion 20 of administration port 16. In an alternative embodiment discussed below, bottom seal 102 of opaque layers 100 may overlie delivery peel seal 90.

(34) Opaque layers 100 illustrated in FIG. 1B may be of the same size and material, e.g., a polymer-coated aluminum foil, although the front and back layers 100 may have different markings and/or indicia. In the illustrated embodiment, bottom seal 102 of opaque layers 100 extends to angled seals 106a and 106b that extend along the widening portions of strong bottom seam 50. Side seals 108a and 108b extend from angled seals 106a and 106b along powdered drug portions 48a and 48b of side seams 40a and 40b, respectively, and in one embodiment such that opaque layers 100 completely cover drug portions 48a and 48b of the side seams. A top seal 110 of opaque layers 100 extends along mixing peel seal 60 and in one embodiment such that opaque layers 100 completely cover the mixing peel seal. All seals of opaque layers 100 are peel seals in one embodiment so that opaque layers 100 may be removed completely from container or bag 10 prior to reconstitution.

(35) Opaque layers 100 extend past angled seals 106a and 106b to form tabs 112a and 112b that hinge up respectively from angled seals 106a and 106b. The user may grasp either of tabs 112a and 112b to remove opaque layers 100 from sheets 12 and 14. Seals 102, 106a, 106b, 108a, 108b and 110 may be formed by heat sealing at a lower temperature than that used to form peel seals 60 and 90. Opaque layers 100 protect the powdered drug in powdered drug chamber 80 from harmful ultraviolet (“UV”) radiation and help to prevent air from entering chamber 80 through sheets 12 and 14.

(36) FIGS. 1A, 2 and 3 illustrate one embodiment for the relative placement between bottom seal 102 of opaque layers 100 and delivery peel seal 90 formed between sheets 12 and 14 of dual chamber bag 10. FIGS. 7A to 7C are side views of dual chamber bag 10 illustrating another embodiment for a relative placement between bottom seal 102 of opaque layers 100 and delivery peel seal 90 formed between sheets 12 and 14. In particular, a relative placement between jutting or trapezoidal portion 104 of bottom seal 102 of opaque layers 100 and non-linear or trapezoidal portion 92 of delivery peel seal 90 is illustrated. For reference, FIGS. 7A to 7C show many of the components of dual chamber bag 10 discussed above including sheets 12 and 14 sealed to administration port 16, wherein administration port 16 includes port body 18 having a tapered sealing portion 20 that extends to a cylindrical outlet portion 22. Tapered sealing portion 20 is sealed between and to sheets 12 and 14. Outlet portion 22 of port body 18 includes a flange 22a at its end for receiving a spike from a mating administration set and to provide an increased area for sealing to tear strip 28.

(37) FIGS. 7A to 7C show opaque layers 100 separated from sheets 12 and 14 to help distinguish between same. In reality, opaque layers 100 directly abut sheets 12 and 14. The dimensions provided in FIGS. 7A to 7C are merely an example but do aptly illustrate one possible relationship between the different peel seals, wherein delivery peel seal 90 at extended portion 92 is 5 mm wide and bottom seal 102 at trapezoidal portion 104 is 9 mm wide. Delivery peel seal 90 and bottom seal 102 of opaque layers 100 may however be of any of the widths discussed above.

(38) The goal in FIGS. 7A to 7C is for bottom seal 102 of opaque layers 100 to completely cover delivery peel seal 90. In FIG. 7A, the alignment between bottom seal 102 of opaque layers 100 and delivery peel seal 90 is perfect, wherein the same overshoot of 2 mm between bottom seal 102 and delivery peel seal 90 exists on both sides of delivery peel seal 90. The seal strengths (force required to open) of seals 102 and 90 will add to increase the overall force needed to open both seals. It is contemplated, however, to instruct the user to remove opaque layers 100 prior to activating either peel seal 60 or 90 of dual chamber bag. The user will then only have to provide the force needed to open delivery peel seal 90, e.g., 6 to 10 N/15 mm, to deliver the mixed drug.

(39) In FIG. 7B, the misalignment of bottom seal 102 of opaque layers 100 to delivery peel seal 90 to the left is the most possible given the manufacturing process employed, wherein an overshoot of 4 mm between bottom seal 102 and delivery peel seal 90 exists to the left of delivery peel seal 90, while no overshoot exists to the right of delivery peel seal 90. Nevertheless, bottom seal 102 still completely covers delivery peel seal 90. Similarly in FIG. 7C, the misalignment of bottom seal 102 of opaque layers 100 to delivery peel seal 90 to the right is the most possible given the manufacturing process employed, wherein an overshoot of 4 mm between bottom seal 102 and delivery peel seal 90 exists to the right of the delivery peel seal 90, while no overshoot exists to the left of delivery peel seal 90. Here again, bottom seal 102 still completely covers delivery peel seal 90. It is accordingly contemplated in FIGS. 7A to 7C to size the width of bottom seal 102 and delivery peel seal 90 so that bottom seal 102 always covers delivery peel seal 90 regardless of manufacturing tolerance.

(40) FIGS. 8A to 8C are side views of dual chamber bag 10 illustrating a further embodiment for a relative placement between bottom seal 102 of opaque layers 100 and, here, two delivery peel seals 90 formed between sheets 12 and 14. In particular, a relative placement between jutting or trapezoidal portion 104 of bottom seal 102 of opaque layers 100 and non-linear or trapezoidal portions 92 of two delivery peel seals 90 is illustrated. For reference, FIGS. 8A to 8C again show many of the components of dual chamber bag 10 discussed above including sheets 12 and 14 sealed to administration port 16, wherein administration port 16 includes port body 18 having a tapered sealing portion 20 that extends to a cylindrical outlet portion 22. Outlet portion 22 of port body 18 again includes a flange 22a at its end.

(41) FIGS. 8A to 8C show opaque layers 100 separated from sheets 12 and 14 to help distinguish between same. Again, opaque layers 100 directly abut sheets 12 and 14 in the commercial embodiment of dual chamber bag 10. The dimensions provided in FIGS. 8A to 8C are merely an example but do aptly illustrate one possible relationship between the different peel seals, wherein both delivery peel seals 90 at extended portions 92 are 3 mm wide, while bottom seal 102 at trapezoidal portion 104 is 7 mm wide. Delivery peel seal 90 and bottom seal 102 of opaque layers 100 may, however, be of any of the widths discussed above.

(42) In FIGS. 8A to 8C, first and second peel seals 90, each having a non-linear or trapezoidal portion 92, are spaced apart from each other by a non-sealed section 94 between sheets 12 and 14. In the illustrated embodiments, the combined width of both peel seals 90, 6 mm, in FIGS. 8A to 8C, is approximately the same as the width of peel seal 90, 5 mm, in FIGS. 7A to 7C. Thus, assuming the same amount of energy is imparted to form peel seals 90 in FIGS. 8A to 8C as the amount of energy imparted to form peel seal 90 in FIGS. 7A to 7C, the seal strength of the combined peel seals 90 in FIGS. 8A to 8C should be roughly equal to the seal strength of peel seal 90 in FIGS. 7A to 7C, namely, about 2 to 10 N/15 mm.

(43) The goal in FIGS. 8A to 8C is for bottom seal 102 of opaque layers 100 to completely cover left delivery peel seal 90 but not at all cover right delivery peel seal 90. In FIG. 8A, the alignment between bottom seal 102 of opaque layers 100 and delivery peel seals 90 is perfect, wherein the same overshoot of 2 mm between bottom seal 102 and left delivery peel seal 90 exists on both sides of left delivery peel seal 90. Right peel seal 90 is not at all covered. As with FIGS. 7A to 7C, it is contemplated to instruct the user to remove opaque layers 100 prior to activating either peel seal 60 or 90 of dual chamber bag, so that only the force needed to open both delivery peel seals 90, e.g., 2 to 10 N/15 mm, is needed to deliver the mixed drug.

(44) In FIG. 8B, the misalignment in the left direction between bottom seal 102 of opaque layers 100 and left delivery peel seal 90 is the most possible given the manufacturing process employed, wherein an overshoot of 4 mm in the left direction between bottom seal 102 and left delivery peel seal 90 exists, while no overshoot exists to the right of delivery peel seal 90. Nevertheless, bottom seal 102 still completely covers left delivery peel seal 90, while right delivery peel seal 90 remains completely uncovered by bottom seal 102.

(45) Similarly in FIG. 8C, the misalignment in the right direction between bottom seal 102 of opaque layers 100 and left delivery peel seal 90 is the most possible given the manufacturing process employed, wherein an overshoot of 4 mm in the right direction between bottom seal 102 and left delivery peel seal 90 exists, while no overshoot exists to the left of left delivery peel seal 90. Nevertheless, bottom seal 102 still completely covers left delivery peel seal 90, while right delivery peel seal 90 remains completely uncovered by bottom seal 102. It is accordingly contemplated in FIGS. 8A to 8C to size the width of bottom seal 102 and left and right delivery peel seals 90 so that bottom seal 102 always covers left delivery peel seal 90, while right delivery peel seal 90 is always uncovered, regardless of manufacturing tolerance.

(46) FIG. 9 illustrates one preferred embodiment for administration port 16, which is different in certain ways than administration port 16 discussed above. As before, administration port 16 includes port body 18 having a tapered sealing portion 20 forming flanges 20a and 20b (shown sectioned in FIG. 9), wherein tapered sealing portion 20 extends to a cylindrical outlet portion 22. Outlet portion 22 of port body 18 again includes a flange 22a for receiving tear strip 28 (illustrated above). Port body 18 is in one embodiment a molded, e.g., injection molded, rigid PP structure.

(47) A compliant or compressible septum, insert or sleeve 24 is fitted sealingly inside outlet portion 22 and flange 22a of administration port 16. Septum 24 may be formed from a medically safe elastomer or rubber, e.g., a thermoplastic elastomer (“TPE”), which accommodates a broad range of spike head diameters provided with the administration sets. Septum 24 may be held in place within rigid outlet portion 22 via bonding, wherein the adhesion occurs in one embodiment via a two shot injection molding process such that the materials of both septum 24 and rigid portion 22 are injected into a same injection mold to increase the bonding between both materials. The resulting bi-injection molding bond is a cohesive bond. If rigid portion 22 and septum 24 are not molded together and are instead separate parts, an adhesive may be used to bond the separate parts together. Adhesion may also be obtained during the moist heat sterilization process. Septum 24 may be unslit and allow the spike of an administration set (not illustrated) to pierce the elastomeric septum 24, which holds the spike due to the resiliency of the material of septum 24. In an alternative embodiment, septum 24 is preslit.

(48) Elastomeric septum 24 provides flexibility, e.g., compressibility, to accept standard sized diameter spikes and non-standard or differently sized spikes. One difference between administration set 16 of FIG. 9 and of the one described above is that a separate membrane 26 is not provided. Here, dual chamber bag 10 relies on the delivery peel seal 90 seal to separate septum 24 and port body 18 from powdered drug 88 prior to use.

(49) In one embodiment, administration port 16 is fully assembled (including tear strip 28) prior to being sealed to sheets 12 and 14 of dual chamber container or bag 10, which in one embodiment is performed prior to the filling of diluent or powdered drug 88. In this way, sealed sheets 12 and 14 and sealed administration port 16 may be sterilized, e.g., steam sterilized, together. Here, tear strip 28 is configured to allow penetration of steam into port body 18, between strip 28 and septum 24 to sterilize all contacted surfaces.

Method of Making

(50) Referring now to FIGS. 10A to 10D, dual chamber bag 10 is illustrated in various stages of manufacture. For purposes of illustration, opaque layers 100 are not shown. Also, only the element numbers relevant for FIGS. 10A to 10D are provided, however, each of the structure, functionality and alternatives discussed for any of the element numbers found in FIGS. 1A to 9 is applicable to dual chamber bag 10 of FIG. 10D (but missing opaque layers 100). FIGS. 10A to 10D illustrate certain differences with the bag version of FIGS. 1A to 6. One difference is that corners 44 in FIGS. 10A to 10D are angled instead of curved. Another difference is that an extra aperture 46 is formed in the version of FIGS. 10A to 10D.

(51) FIGS. 10A, 10B and 10C illustrate that in formative stages of dual chamber bag 10, there are portions of certain peripheral edges of the bag where sheets 12 and 14 are not sealed together to have a strong seal. Those edges are indicated in dashed line. In particular, FIGS. 10A, 10B and 10C illustrate via dashed line 128 that sheets 12 and 14 are unsealed at powdered drug strong seal portions 48b, which is illustrated as being sealed in FIG. 10D. Additionally, FIG. 10A illustrates via dashed line 130 that sheets 12 and 14 are unsealed at upper seam area 34a, which is illustrated as being sealed in FIGS. 10B to 10D.

(52) FIGS. 10A and 10B also illustrate that during the formative stages of dual chamber bag 10, an additional lateral and temporary peel seal 120 is provided. Lateral peel seal 120 includes a first end 122 that extends to strong bottom seam 50 and a second end 124 that extends to side 40b. Temporary peel seal 120 has a length sufficient to provide a suitable opening to receive powdered drug 88 in a later manufacturing step. In a non-limiting example, lateral peel seal 120 may be about 2 mm to about 10 mm wide and about 50 mm to about 90 mm long and have the same seal strength (force required to open), greater seal strength or a lower seal strength than delivery peel seal 90. In an embodiment, lateral peel seal 120 may have a seal strength of approximately seal of 1 to 5 N/15 mm, and in one embodiment be 3 N/15 mm.

(53) Lateral peel seal 120 in the illustrated embodiment is initially formed with a small opening or aperture 126, which is sized to accept a discharge tube or nozzle of an injection gas filling station (not illustrated). Opening or aperture 126 may, for example, be long enough to accept a 6 mm to 10 mm outer diameter inert gas filling tube or nozzle. The injection gas may be an inert gas such as nitrogen, argon, carbon dioxide or mixtures thereof. If it becomes imperative to remove as much oxygen as possible from drug chamber 80, an oxygen “getter” gas, such as hydrogen or silane may be used instead or in combination with any one or more of the inert gases mentioned above.

(54) In the formative manufacturing stage of FIG. 10A, it should be appreciated that the majority of strong seals described above have been formed, mixing peel seal 60 and delivery peel seal 90 have been formed according to their specifications discussed above, administration port 16 has been fully formed including tear strip 28, and administration port 16 has been inserted into and sealed to center section 54 of bottom strong seal 50. Dual chamber bag 10 is open (not strong sealed) at the dashed line sections that eventually form powdered drug portion 48b of side seam 40b (lateral dashed line 128) and upper seam area 34a (upper dashed line 130). Lateral peel seal 120 is in tact and has been formed with opening or aperture 126.

(55) The formative manufacturing stage of FIG. 10A may be said to be an initial filling stage in which diluent is introduced into diluent chamber 70 and an inert and/or getter gas is introduced into drug chamber 80. In particular, diluent, e.g., dextrose or saline, may be pumped or gravity fed (in either case metered precisely) at a desired volume into diluent chamber 70 through the opening between sheets 12 and 14 formed at dashed line 130. In one embodiment, immediately after the delivery of diluent into diluent chamber 70, the opening between sheets 12 and 14 formed at dashed line 130 is sealed with a strong seal via any of the sealing methods discussed herein, such that upper seam 30 is fully formed (i) with upper seam at area 34a having oval 34 and (ii) to have a desired strong sealing strength.

(56) Any of the gases or blends discussed above may be injected, e.g., under a slight pressure so as not unduly stress dual chamber container 10, into drug chamber 80 at a desired volume through opening or aperture 126 formed in lateral peel seal 120. Opening or aperture 126 may be sized to be large enough to allow air to be flushed out of drug chamber 80 around the outside of the inert gas delivery nozzle or tube by the injection of inert (and/or getter) gas. Or, if opening or aperture 126 more or less seals to the gas delivery nozzle or tube, a second small opening (not illustrated) may be provided to vent air pushed out of drug chamber 80 by the injected gas.

(57) In one embodiment, immediately after the injection of the inert (and/or getter) gas, opening or aperture 126 (and second opening if provided) is sealed via any of the sealing methods discussed herein, such that lateral peel seal 120 is fully formed to have a desired sealing strength. The injected gas is thereby trapped within drug chamber 80 and is provided in a quantity such that sheets 12 and 14, at least over a majority of drug chamber 80, are separated. The injected gas servers dual purposes, namely, to (i) remove oxygen to help sterility and (ii) maintain sheets 12 and 14 to form a spaced relationship between the sheets, which helps to prevent the sheets from sticking to each other and also aids in the eventual opening of lateral peel seal 120, as discussed in more detail below.

(58) Each of the above-described steps performed in connection with FIG. 10A, and any steps leading up to FIG. 10A, may be performed in a non-aseptic environment. The steps in connection with FIG. 10B however are performed in a sterilizing, e.g., steam sterilizing, environment. As discussed above, opening or aperture 126 no longer exists in lateral peel seal 120 of FIG. 10B. Upper seam 30 having upper seam at area 34a is fully formed and trimmed from the width illustrated in FIG. 10A (or folded over for extra strength along upper seam) so as to have a desired width, and such that dashed line 130 forming the diluent filling opening no longer exists.

(59) If steam sterilized, dual chamber container or bag 10 at FIG. 10B is placed in an autoclave (along with many other such bags or containers) and subjected to steam for a designated amount of time. As mentioned above, steam is able to penetrate tear strip 28 to reach all surfaces of within administration port 16 between tear strip 28 and septum or insert 24. It has also been found that while the remainder of the inside of administration port 16, the inside of delivery administration area 98, and the inside of drug chamber 80 are relatively dry, that steam sterilization nonetheless adequately sterilizes those inner volumes and the surfaces forming same. If needed, it is contemplated to increase the humidity of the inert and/or getter gas delivered to the diluent chamber 80 to, e.g., fifty to one-hundred percent humidity, to aid the steam sterilization of the drug chamber. Diluent chamber 70 having been filled with diluent is readily sterilized under steam sterilization. After steam sterilization, dual chamber bags 10 are allowed to dry, either in a stationary location and/or during transit.

(60) After steam sterilization in FIG. 10B, container or bag 10 is dried and moved in an aseptic manner from the sterilizing station, e.g., steam sterilization autoclave, into a cleanroom which has a classification suitable for handling powdered drug 88. In FIG. 10C, once inside the cleanroom, lateral peel seal 120 is opened. Because drug chamber 80 contains injected gas, sheets 12 and 14 are separated from each other, thereby providing support for opposing suction cups (or other structure) to assist in forming a suction attachment with drug chamber 80 and to ensure that a resulting pulling force is applied only to the sheet 12 or 14 to which the cup is in contact.

(61) In one embodiment, with the injected gas maintaining sheets 12 and 14 in an open condition throughout at least a portion of drug chamber 80, at least one suction cup (not illustrated) is suctioned to each of separated sheets 12 and 14. In an embodiment, the at least one suction cup for sheet 12 is located approximately midway between peel seals 60 and 90 but closer to lateral peel seal 120 than to powdered drug portion 48a of side seam 40a, e.g., one-third or one-quarter of the total width away from lateral peel seal 120 and two-thirds or three-quarters, respectively, of the total width away from powdered drug portion 48a of side seam 40a. The at least one suction cup for sheet 14 is likewise located approximately midway between peel seals 60 and 90 but closer to lateral peel seal 120 than to powdered drug portion 48a of side seam 40a, e.g., one-third or one-quarter of the total width away from lateral peel seal 120 and two-thirds or three-quarters, respectively, of the total width away from powdered drug portion 48a of side seam 40a.

(62) Once suctioned to sheets 12 and 14, the suction cups are moved apart a specified distance to open lateral peel seal 120 a desired amount for powdered drug filling, and at a specified speed so as not to create undue force that may inadvertently open either one or both of peel seals 60 and 90. The suctioning, e.g., pneumatic, used to suction the cups to sheets 12 and 14 may be terminated to release sheets 12 and 14 before, during or after the delivery of powdered drug 80, as desired or needed. If before drug delivery, the insertion of a powdered drug insertion nozzle or tube (not illustrated) may be precise and forceful enough to fit through opened lateral peel seal 120 even if sheets 12 and 14 close together at dashed line 128 partially or fully. If during or after drug delivery, the insertion of a powdered drug nozzle or tube may rely on the suction cups to maintain lateral peel seal 120 in an open state so that the powdered drug nozzle or tube may readily enter drug chamber 80 to deliver the powdered drug.

(63) Any of the powdered drugs listed herein may be injected and/or gravity fed in a metered and known quantity into drug chamber 80 after lateral peel seal 120 has been opened. As discussed earlier, such filling is performed in an aseptic, cleanroom environment.

(64) In FIG. 10D, container or bag 10 filled will both diluent and powdered drug 88 is moved, for example, along a conveyor line within the cleanroom to a bag sealing mechanism that provides a final strong seal at powdered drug portion 48b of side seam 40b, where lateral peel seal 120 resided previously. Dual chamber container or bag 10 is fully formed in FIG. 10D except for two final steps, namely, (i) the peel seal application of removable cover or foil layers 100, one layer 100 each to either side of drug chamber 80 and (ii) the overpouching of dual chamber container or bag 10 having the applied removable cover or foil layers 100.

(65) The formation of dual chamber container or bag 10 has been described in detail in connection with FIGS. 10A to 10D. FIG. 11 illustrates one method 150 listing the steps discussed above without the detail just provided, but wherein such detail is expressly incorporated. The order of the steps in FIG. 11 may be changed as needed or desired (for example, blocks 154, 156 and 160 could be in a different order, while blocks 168 and 170 could be in a different order).

(66) At oval 152, method 150 begins.

(67) At block 154, the majority of strong seals are formed, leaving upper and lateral openings.

(68) At block 156, the mixing, delivery and lateral (with opening) peel seals are formed.

(69) At block 158, the bags are separated if formed together.

(70) At block 160, the administration port is fully formed.

(71) At block 162, the administration port is sealed to the bag sheets.

(72) At block 164, diluent is metered into the diluent chamber through the upper opening.

(73) At block 166, gas is injected into the drug chamber through the lateral opening.

(74) At block 168, the upper opening between the bag sheets is strong sealed closed.

(75) At block 170, the opening in the lateral peel seal is weak peel sealed closed.

(76) At block 172, the bag with diluent and injection gas is moved to sterilization station.

(77) At block 174, the bag including the administration port is sterilized and dried.

(78) At block 176, the sterilized bag is moved aseptically to a cleanroom.

(79) At block 178, the lateral peel seal is opened inside the cleanroom.

(80) At block 180, powdered drug is metered into the drug chamber through the opened lateral peel seal.

(81) At block 182, the lateral opening between the bag sheets is strong sealed.

(82) At block 184, opaque or foil seals are weak sealed to the bag sheets.

(83) At block 186, the dual chamber container or bag is overpouched.

(84) At oval 188, method 150 ends.

Alternative Method of Making

(85) Referring now to FIGS. 12A to 12E, dual chamber bag 10 is illustrated in various intermediate stages of manufacture using an alternative method than method 150. Again, for purposes of illustration, opaque layers 100 are not shown. Also, only the element numbers relevant for FIGS. 12A to 12E are provided; however, each of the structure, functionality and alternatives discussed for any of the element numbers found in FIGS. 1A to 9 is applicable to dual chamber bag 10 prepared via the intermediate steps of FIGS. 12A to 12E. FIGS. 12A to 12E are similar to FIGS. 10A to 10D in that corners 44 in FIGS. 12A to 12E are angled instead of curved. Another similarity is that an extra aperture 46 is formed in FIGS. 10A to 10D and 12A to 12E.

(86) FIG. 12A illustrates that in formative stages of dual chamber bag 10, there are portions of certain peripheral edges of the bag where sheets 12 and 14 are not sealed together to have a strong seal. Those edges are indicated in dashed line. In particular, FIG. 12A illustrates via dashed line 128 that sheets 12 and 14 are unsealed at powdered drug strong seal portion 48a, which is illustrated as being sealed in FIGS. 1A to 3, for example. Additionally, FIG. 12A illustrates via dashed line 208 that sheets 12 and 14 are unsealed at the diluent portion of side seam 40a, which is likewise illustrated as being sealed in FIGS. 1A to 3, for example. Notably, dashed line 130 in FIG. 10A is not provided in FIG. 12A and is not needed to fill diluent chamber 70 with diluent in the method of making associated with FIGS. 12A to 12E. Upper seam area 34a of upper seam 30 may be formed with the other strong seals of container or bag 10 as illustrated in FIG. 12A.

(87) As with FIGS. 10A and 10B, FIG. 12A illustrates that during the formative stages of dual chamber bag 10, additional lateral peel seal 120 is provided. As before, lateral peel seal 120 includes a first end 122, second end 124 and small opening or aperture 126, which is sized to accept a discharge tube or nozzle of an injection gas filling station (not illustrated). Peel seal 120 again has a length sufficient to provide a suitable opening to receive powdered drug 88. Lateral peel seal 120 may again be about 2 mm to about 10 mm wide and about 50 mm to about 90 mm long and have the same seal strength (force required to open), greater seal strength or a lower seal strength than delivery peel seal 90. Lateral peel seal 120 may again have a seal strength of approximately seal of 1 to 5 N/15 mm, and in one embodiment be 3 N/15 mm.

(88) The primary difference between the formative stage of container or bag in FIGS. 12A to 12E and that of FIGS. 10A to 10C is that in FIG. 12A a second lateral and temporary peel seal 200 is provided to aseptically fill diluent chamber 70. Lateral peel seal 200 is provided in place of the upper portion of strong side seal 40a. It should be appreciated in viewing FIGS. 10A to 10C and 12A that lateral and temporary peel seals 120 and 200 may be placed on either side 40a or 40b of the bag. Moreover, in FIG. 12A, lateral peel seals 120 and 200 may be placed on the same or opposing sides of the bag.

(89) Diluent peel seal 200 may be formed to be the same as or slightly different than powdered drug peel seal 120. Diluent peel seal 200 includes a first end 202 that extends to curved or angled corner 44 and a second end 204 that extends to upper seam 30. Diluent peel seal 200 has a length sufficient to provide a suitable opening to receive diluent in a later manufacturing step. In a non-limiting example, diluent peel seal 200 may be about 2 mm to about 10 mm wide and about 50 mm to about 90 mm long and have the same seal strength (force required to open), greater seal strength or a lower seal strength than delivery peel seal 90. In an embodiment, diluent peel seal 200 may have a seal strength of approximately seal of 1 to 5 N/15 mm, and in one embodiment be 3 N/15 mm.

(90) Diluent peel seal 200 in the illustrated embodiment is initially formed with a small opening or aperture 206, which is sized to accept a discharge tube or nozzle of an injection gas filling station (not illustrated). Opening or aperture 206 may for example be long enough to accept a 6 mm to 10 mm outer diameter injection gas filling tube or nozzle. The injection gas may again be inert, such as nitrogen, argon, carbon dioxide or mixtures thereof and/or include an oxygen “getter” gas, such as hydrogen or silane.

(91) Primary differences between the method of making in FIGS. 10A to 10D and that of FIGS. 12A to 12E is that in FIGS. 12A to 12E, (i) filling of both drug 88 and diluent is done aseptically in a cleanroom and (ii) two lateral and temporary peel seals 120 and 200 are employed. FIG. 12A is formed in a non-ascetic environment. In the non-ascetic environment, the majority of strong seals (except at dashed lines 128 and 208) are formed, mixing peel seal 60 and delivery peel seal 90 are formed according to their specifications discussed above, administration port 16 is fully formed including tear strip 28, and administration port 16 is inserted into and sealed to center section 54 of bottom strong seal 50. Lateral drug peel seal 120 (with opening 126) and lateral diluent peel seal 200 (with opening 206) are also formed according to their specifications discussed above.

(92) Next, injection gas is introduced into powdered drug chamber 80 and diluent chamber 70 via openings 126 and 206, respectively. Openings 126 and 206 are then immediately closed to trap injection the gas within chambers 70 and 80.

(93) Next, each empty (except for injection gas) container or bag of FIG. 12A is sterilized. Because the bag of FIG. 12A is empty, steam sterilization is not optimal. Nevertheless, steam sterilization could be employed. Sterilization via ethylene oxide is also an option. More likely, however, the containers or bags of FIG. 12A are irradiated, e.g., gamma or electron beam (Ebeam) radiation, sterilized. Once sterilized, the bags of FIG. 12A are delivered in an aseptic manner to a cleanroom. In an embodiment, if multiple containers are formed together, they are separated at some point prior to entering the cleanroom.

(94) FIGS. 12B to 12E illustrate what happens to the container or bag of FIG. 12A once inside the cleanroom. In FIG. 12B, once inside the cleanroom, lateral drug peel seal 120 is opened. Because drug chamber 80 contains injected gas, sheets 12 and 14 are separated from each other, thereby providing support for opposing suction cups (or other structure) to assist in forming a suction attachment with drug chamber 80 and to ensure that a resulting pulling force is applied only to the sheet 12 or 14 to which the cup is in contact. The use of suction cups or any other device for providing a pulling force, and all structure, functionality and alternatives for same discussed above in connection with FIG. 10C, is equally applicable to the opening of lateral drug peel seal 120 of FIG. 12B.

(95) With peel seal 120 of FIG. 12B opened, leaving the opening illustrated by dashed line 128, any of the powdered drugs listed herein may be injected and/or gravity fed in a metered and known quantity into drug chamber 80. Such filling is performed in the aseptic, cleanroom environment. Notably, in FIG. 12B, lateral diluent peel seal 200 for diluent chamber 70 remains in tact.

(96) In FIG. 12C, with powdered drug 88 injected into powdered drug chamber 80, powdered drug portion 48a of strong side seam 40a is formed aseptically, completing powdered drug chamber 80 and trapping powdered drug 88 within same. Notably, in FIG. 12C, lateral diluent peel seal 200 for diluent chamber 70 remains in tact.

(97) In FIG. 12D, lateral diluent peel seal 200 is opened. Because diluent chamber 70 contains injected gas, sheets 12 and 14 are separated from each other, thereby providing support for opposing suction cups (or other structure) to assist in forming a suction attachment with diluent chamber 70 and to ensure that a resulting pulling force is applied only to the sheet 12 or 14 to which the cup is in contact. The use of suction cups or any other device for providing a pulling force, and all structure, functionality and alternatives for same discussed above in connection with FIG. 10C, is equally applicable to the opening of lateral diluent peel seal 200 of FIG. 12D.

(98) With temporary peel seal 200 of FIG. 12D opened, leaving the opening illustrated by dashed line 208, any of the diluents listed herein may be injected and/or gravity fed in a metered and known quantity into diluent chamber 70. Such filling is likewise performed in the aseptic, cleanroom environment.

(99) In FIG. 12E, with diluent injected into diluent chamber 70, diluent portion of strong side seam 40a between curved or angled corner 44 and upper seam 30 is formed aseptically, completing diluent chamber 70 and trapping the diluent within same. In FIG. 12E, dual chamber container or bag 10 is substantially formed except for the opaque layers 100 and the overpouch.

(100) It should be appreciated that for both the methods of FIGS. 10A to 10D and 12A to 12E, an in-process control step in which the desired quantity of powdered drug 88 is verified to have been metered to powdered drug chamber 80. Such check may be made via one or both of a load cell sensor and/or a vision check. With the load cell, one or both of a weight of drug 88 added to container or bag 10 and/or a weight of drug 88 removed from a supply may be analyzed. Also, containers or bags 10 at FIGS. 10D and 12E may be washed and dried prior to the addition of opaque layers 100, all of which may be performed non-aseptically along with the addition of the overpouch. Further, for both the methods of FIGS. 10A to 10D and 12A to 12E, container or bag 10 may be leak checked prior to overpouching.

(101) An alternative formation of dual chamber container or bag 10 has been described in detail in connection with FIGS. 12A to 12E. FIG. 13 illustrates one method 210 listing the steps discussed above without the detail just provided, but wherein such detail is expressly incorporated. The order of the steps in FIG. 13 may be changed as needed or desired (for example, aseptic filling of diluent may occur before aseptic filling of powdered drug 80, formation of seals may be switched, and administration port 16 may be formed at any time prior to its sealing).

(102) At oval 212, method 210 begins.

(103) At block 214, the majority of strong seals are formed, leaving drug and diluent lateral openings.

(104) At block 216, the mixing, delivery, and drug and diluent lateral (with openings) peel seals are formed.

(105) At block 218, the bags are separated if formed together.

(106) At block 220, the administration port is fully formed.

(107) At block 222, the administration port is sealed to the bag sheets.

(108) At block 224, gas is injected into the drug chamber through the lateral drug peel seal opening.

(109) At block 226, the lateral drug peel seal opening is weak peel sealed closed.

(110) At block 228, gas is injected into the diluent chamber through the lateral diluent peel seal opening.

(111) At block 230, the lateral diluent peel seal opening is weak peel sealed closed.

(112) At block 232, the bag with injection gas in both chambers is moved to a sterilization station.

(113) At block 234, the bag including the administration port is sterilized, e.g., gamma radiation sterilized.

(114) At block 236, the sterilized bag is moved aseptically to a cleanroom.

(115) At block 238, the lateral drug peel seal is opened inside the cleanroom.

(116) At block 240, powdered drug is metered into the drug chamber through the opened drug peel seal aseptically.

(117) At block 242, the opened drug peel seal is strong sealed closed.

(118) At block 244, the lateral diluent peel seal is opened inside the cleanroom.

(119) At block 246, diluent is metered into the diluent chamber through the opened diluent peel seal aseptically.

(120) At block 248, the opened diluent peel seal is strong sealed closed.

(121) At block 250, opaque or foil seals are weak sealed to the bag sheets.

(122) At block 252, the dual chamber container or bag is overpouched.

(123) At oval 254, method 210 ends.

Product Using Dual Chamber Bag

(124) To reduce the volume and weight of powdered drug 88 needed, and to reduce the amount of aseptic filling that needs to be performed, it is contemplated to remove one or more component of dry drug powder 88 and to provide it instead with the liquid diluent. Components suitable for removal from the drug powder include buffers, tonicity adjusters or other soluble components normally provided with the powder. The removed component is provided instead in the liquid diluent, which may be particularly beneficial if there is a risk of interaction between the powdered components.

(125) Similarly, it is possible that in the event that a very small volume of drug powder 88 is required, some fraction of the dextrose or sodium chloride ordinarily dissolved in the diluent might instead be provided in powder 88 to increase its volume for greater ease of handling.

(126) It should be understood that various changes and modifications to the presently preferred embodiments described herein will be apparent to those skilled in the art. Such changes and modifications can be made without departing from the spirit and scope of the present subject matter and without diminishing its intended advantages. It is therefore intended that such changes and modifications be covered by the appended claims. For example, while the structure and functionality have been described in connection with a flexible bag, certain structure and functionality described herein are applicable to other types of fluid containers, such as other medical fluid containers. Also, while the structure and functionality have been described in connection with a dual chamber container, much of the structure and functionality described herein are applicable to containers having a single chamber or three or more chambers. Moreover, in an alternative embodiment, the gas insertion into the powdered drug chamber may be performed in the cleanroom after sterilization. In a further alternative embodiment, the powdered drug may be filled through the administration port instead of through the lateral peel seal, wherein the administration port is thereafter fitted with or formed to have septum or insert 24.